Showing results (1-10 of 122) with videos related to
Sort By:
Pageof 13
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2026
Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain: CROMMAS StudyEnrique M Ocio, María-Victoria Mateos, Expert Review of Hematology|November 19, 2010
Novel treatment regimens for Waldenström's macroglobulinemiaRamón García-Sanz, Enrique M OcioInvestigational New Drugs|December 2, 2010
The DAC system and associations with multiple myelomaEnrique M Ocio, Jesús F San MiguelCancers|June 2, 2021
Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma ProgressionPatricia Maiso, Pedro Mogollón, Enrique M Ocio, et al.Expert Opinion on Investigational Drugs|May 25, 2012
Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDsEnrique M Ocio, Maria-Victoria Mateos, Jesus F San-MiguelAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Induction Therapy for Newly Diagnosed Multiple MyelomaBarry Paul, Brea Lipe, Enrique M Ocio, et al.Seminars in Oncology|October 19, 2013
Novel generation of agents with proven clinical activity in multiple myelomaMaría-Victoria Mateos, Enrique M Ocio, Jesús F San MiguelExpert Opinion on Investigational Drugs|December 10, 2019
Filanesib for the treatment of multiple myelomaEsperanza Macarena Algarín, Susana Hernández-García, Mercedes Garayoa, et al.Expert Review of Hematology|December 20, 2013
Future agents and treatment directions in multiple myelomaEnrique M Ocio, Constantine S Mitsiades, Robert Z Orlowski, et al.Investigational New Drugs|July 10, 2012
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implicationsAntonio Garcia-Gomez, Enrique M Ocio, Atanasio Pandiella, et al.Pageof 13